Pharmaceutical Executive April 22, 2024
Mike Hollan

Alder, CEO of Gain Therapeutics, discusses how the Magellan platform was used in the creation of GT-02287.

Gain Therapeutics is in the clinical trials phase for a new Parkinson’s treatment known as GT-02287, which may be able to prevent symptoms from worsening or even occurring. The company’s CEO, Mattias Alder, spoke with Pharmaceutical Executive about the drug and how an AI-powered platform was used to develop it.

PE: Can you discuss the GT-02287 study and the results?
Mattias Alder: When I joined the company about two-and-a-half years ago, we had just received data from patient-derived cells which showed that the drug has an effect in terms of actually restoring critical enzymes in terms of cell survival. Since then, we’ve moved all...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Biotechnology, Clinical Trials, Interview / Q&A, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Technology, Trends
Related Articles:
UK sets out position on regulating AI as a medical device
AI: A powerful tool for improving health care efficiency and safety
Enhancing Global Mental Health Care With Digital Tools and AI for Scalable Interventions
How AI can accelerate prior and concurrent authorization processes
Profluent releases AI-enabled OpenCRISPR-1 to edit the human genome

Share This Article